ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Statin and Other Antilipemic Use and Prostate Cancer: Results from the EPICAP Study.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cholesterol metabolism and aggressive prostate cancer: clarifying the signal from EPICAP.Translational andrology and urology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
backgroundAntilipemic drugs have been hypothesized to decrease the risk of several cancers; however, results are still conflicting for prostate cancer.
methodsWe used data from the EPICAP study, a French population-based case-control study including 819 incident prostate cancer cases and 879 population-based controls frequency-matched by age. Detailed information on the use of antilipemic drugs has been collected.
resultsThe use of overall antilipemic drugs was not associated with prostate cancer risk, whereas the use of statins, and particularly lipophilic statins, was inversely associated with high-grade prostate cancer with an International Society of Urological Pathology score ≥4 [OR = 0.52; 95% confidence interval (CI), 0.27-1.00; OR = 0.30; 95% CI, 0.12-0.77, respectively]. When taking into account the duration of use, long duration (≥10 years) of statin and lipophilic statin was inversely associated with prostate cancer overall (OR = 0.69; 95% CI, 0.47-1.01; OR = 0.54; 95% CI, 0.35-0.85, respectively) and with high-grade prostate cancer (OR = 0.49; 95% CI, 0.24-1.01; OR = 0.26, 95% CI, 0.09-0.72, respectively).
conclusionsOur results showed an inverse association between high-grade prostate cancer and statins, particularly lipophilic statins, and indicated that these associations were more pronounced for long duration. IMPACT: In a context of overdiagnosis and overtreatment, identifying factors associated with aggressive prostate cancers is important and could help improving targeted screening strategies.
Indexed as
Identifiers
41071197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.